Novartis Faces Patent Cliff and Bets on Pipeline to Offset Revenue Losses
Biotech M&A has surged in 2026 as pharmaceutical companies seek to offset patent expirations. Novartis (NVS) is facing significant revenue declines from Entresto due to generic competition, with a projected $4 billion loss this year. CEO Vas Narasimhan is relying on three late-stage drug trials expected later this year to mitigate these losses.